Earlier studies showed that HF management in primary care is far from optimal, with underprescription of angiotensin-converting enzyme inhibitors (ACEIs) (or in the case of intolerance, angiotensin receptor blockers (ARBs)) and beta-blockers [7–10]. The gene discussed is ACE; the disease is hydrops fetalis.